{
    "nctId": "NCT05656079",
    "briefTitle": "To Evaluate the Cardiac Safety of Pegylated Liposomal Doxorubicin Concurrently Plus Trastuzumab and Pertuzumab in the Adjuvant Setting for Early-stage HER-2-positive Breast Cancer: a Multicenter, Randomized Controlled Clinical Study",
    "officialTitle": "To Evaluate the Cardiac Safety of Pegylated Liposomal Doxorubicin Concurrently Plus Trastuzumab and Pertuzumab in the Adjuvant Setting for Early-stage HER-2-positive Breast Cancer: a Multicenter, Randomized Controlled Clinical Study",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 204,
    "primaryOutcomeMeasure": "1-year incidence of cardiotoxicity",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. 18-70 years old, Female;\n2. Subjects with histopathologically confirmed invasive breast cancer;\n3. HER2-positive breast cancer (Immunohistochemistry score of 3+ or fluorescence in situ hybridization positivity);\n4. No distant metastasis;\n5. Lymph node positive or negative, primary tumour\u22652cm;\n6. Lymph node negative\uff0cprimary tumour\u22642cm and any of the following factors; 1) Histological grade 3; 2) ER negative (\\<10%) and PR negative (\\<20%); 3) Age\\<35 years old; 4) Pathological hint: vascular invasion or intravascular cancer thrombus;\n7. Surgery was completed and chemotherapy was started within 8 weeks after surgery;\n8. Before and after chemotherapy LVEF\u226555%;\n9. ECOG performance status of 0-1;\n10. Signed the informed consent.\n\nExclusion Criteria:\n\n1. Subjects who are known to be allergic or intolerant to chemotherapy drugs or their excipients;\n2. Previously suffered from invasive breast cancer, and other malignant tumors within 5 years (excluding carcinoma in situ of the cervix, carcinoma in situ of the rectum, carcinoma in situ of melanoma, basal cell carcinoma of the skin, and squamous cell carcinoma);\n3. For breast cancer, have received any anti-tumor therapy before randomization (except surgical treatment before enrollment);\n4. Hematopoietic function, renal function and liver function meet one of the following conditions: 1) Neutrophil count \u22641.5\u00d7109/L; 2) Platelet count \u2264 50\u00d7109/L; 3) Hemoglobin \u2264 8.0g/dL; 4) Creatinine clearance rate \u226430ml/min; 5) AST and ALT \u2265 2.5 times the upper limit of normal in subjects without liver metastases; 6) Bilirubin \u2265 2 times the upper limit of normal; 7) APTT/PT\u22651.5 times the upper limit of normal;\n5. Have a history of cardiovascular disease or associated with severe cardiovascular disease, lung disease;\n6. Active hypertension: systolic blood pressure \u2265 180mmHg, diastolic blood pressure \u2265 90mmHg;\n7. NYHA cardiac insufficiency grading \u2265 \u2162 grade;\n8. Severe, uncontrollable systemic disease;\n9. Subjects who are pregnant or breastfeeding, or subjects who cannot ensure effective contraceptive measures during the study treatment;\n10. Subjects who participated in other clinical trials at the same time;\n11. Subjects determined by the investigator to be inappropriate to participate in this study.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}